A Study With OPTIVATE® in People With Von Willebrand Disease
Status:
Terminated
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The main objective of the study is to assess the pharmacokinetics of OPTIVATE® after a single
dose of 80 IU/kg VWF:RCo. The secondary objectives of the study are to assess efficacy and
safety of OPTIVATE® in long-term use over at least 12 months.